Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth
文献类型:期刊论文
作者 | Liu, Ningning ; Li, Xiaofen ; Huang, Hongbiao ; Zhao, Chong ; Liao, Siyan ; Yang, Changshan ; Liu, Shouting ; Song, Wenbin ; Lu, Xiaoyu ; Lan, Xiaoying ; Chen, Xin ; Yi, Songgang ; Xu, Li ; Jiang, Lili ; Zhao, Canguo ; Dong, Xiaoxian ; Zhou, Ping ; Li, Shujue ; Wang, Shunqing ; Shi, Xianping ; Dou, Ping Q. ; Wang, Xuejun ; Liu, Jinbao |
刊名 | ONCOTARGET
![]() |
出版日期 | 2014 |
卷号 | 5期号:14页码:5453-5471 |
ISSN号 | 1949-2553 |
学科主题 | Oncology ; Cell Biology |
语种 | 英语 |
公开日期 | 2016-12-16 |
源URL | [http://ir.gibh.ac.cn/handle/344009/312] ![]() |
专题 | 广州生物医药与健康研究院_华南干细胞与再生医学研究所_华南干细胞与再生医学研究所_期刊论文 |
推荐引用方式 GB/T 7714 | Liu, Ningning,Li, Xiaofen,Huang, Hongbiao,et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth[J]. ONCOTARGET,2014,5(14):5453-5471. |
APA | Liu, Ningning.,Li, Xiaofen.,Huang, Hongbiao.,Zhao, Chong.,Liao, Siyan.,...&Liu, Jinbao.(2014).Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.ONCOTARGET,5(14),5453-5471. |
MLA | Liu, Ningning,et al."Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth".ONCOTARGET 5.14(2014):5453-5471. |
入库方式: OAI收割
来源:广州生物医药与健康研究院
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。